A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
ALX Oncology Inc.
EMD Serono
Seagen Inc.
Seagen Inc.
Compass Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
BioNTech SE
Genentech, Inc.
AstraZeneca
Hummingbird Bioscience
Boehringer Ingelheim
Bristol-Myers Squibb
AbbVie
Janssen Research & Development, LLC
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
AVEO Pharmaceuticals, Inc.
Exscientia AI Limited
KaliVir Immunotherapeutics
Pfizer
Fate Therapeutics
Alpha Tau Medical LTD.
DualityBio Inc.
Tempus AI
AstraZeneca
Zumutor Biologics Inc.
Aulos Bioscience, Inc.
Ipsen
Merus B.V.
IDEAYA Biosciences
Radiopharm Theranostics, Ltd
EpiBiologics
AstraZeneca
Regeneron Pharmaceuticals
Bicara Therapeutics
Terremoto Biosciences Inc.
Coherus Oncology, Inc.
Ensem Therapeutics
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Exelixis
Tubulis GmbH
Alentis Therapeutics AG
Eli Lilly and Company
Neonc Technologies, Inc.
Sumitomo Pharma America, Inc.
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc